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Background: It has previously been shown that indirubin derivative E804 (IDR-E804) blocks signal transducer and
activator of transcription-3 signaling in human breast and prostate cancer cells and inhibits Src kinase activity. To
further establish its role in angiogenesis, we tested its potential using human umbilical vein endothelial cells
(HUVECs) and analyzed the effects of IDR-E804 on cellular and molecular events related to angiogenesis.
Methods: The anti-angiogenic effects of IDR-E804 were examined by assessing the proliferation, migration and
capillary tube formation of HUVECs were induced by vascular endothelial growth factor (VEGF) with or without
various concentrations of IDR-E804. The inhibitory effect of IDR-E804 angiogenesis and tumor growth in vivo was
also investigated in Balb/c mice subcutaneously transplanted with CT-26 colon cancer cells.
Results: IDR-E804 significantly decreased proliferation, migration and tube formation of vascular endothelial growth
factor VEGF-treated HUVECs. These effects were accompanied by decreased phosphorylation of VEGF receptor
(VEGFR)-2, AKT and extracellular signal regulated kinase in VEGF-treated HUVECs. Intratumor injections of IDR-E804
inhibited the growth of subcutaneously inoculated CT-26 allografts in syngenic mice. Immunohistochemistry
revealed a decreased CD31 microvessel density index and Ki-67 proliferative index, but an increased apoptosis index
in IDR-E804-treated tumors.
Conclusions: These data revealed that IDR-E804 is an inhibitor of angiogenesis and also provide evidence for the
efficacy of IDR-E804 for anti-tumor therapies.
Keywords: Angiogenesis, Indirubin derivative E804, Vascular endothelial growth factor receptor-2, Human umbilical
vein endothelial cells, TumorBackground
Angiogenesis has been described as one of the hallmarks
of cancer, playing a fundamental role in tumor growth,
invasion and metastasis [1]. Under many pathological
conditions, including chronic inflammation, diabetic ret-
inopathy, rheumatoid arthritis or atherosclerosis, persist-
ent upregulated angiogenesis is a common feature [2,3].
Thus, understanding of the central importance of angio-
genesis and how new blood vessels are formed has led to
novel therapies designed to interrupt this process [2-4].
Angiogenesis is tightly controlled by balancing the
activity of various angiogenic factors [2]. Numerous
pathways contribute to tumor angiogenesis including
vascular endothelial growth factor (VEGF), fibroblast
growth factor, and platelet-derived growth factor [4].
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reproduction in any medium, provided the origis essential in the process of angiogenesis [5]. VEGF
binds to two tyrosine kinase receptors, VEGF receptor
(VEGFR)-1 and VEGFR-2 [4-6]. Signaling through
VEGFR-1 and VEGFR-2 are important for embryonic de-
velopment [5]. Although the affinity of VEGFR-2 for
VEGF is lower than that of VEGFR-1, VEGFR-2 more
potently stimulates endothelial cell proliferation and mi-
gration than VEGFR-1 [5,6]. Moreover, VEGFR-2 expres-
sion is almost entirely restricted to vascular endothelial
cells and it has been reported that VEGFR-2 expression
was markedly up-regulated during chronic inflammation,
wound repair and tumor growth [5,6].
VEGF binding to the extracellular domain of VEGFR-2
results in dimerization and autophosphorylation of the
intracellular tyrosine kinases [4-6]. This activates mul-
tiple downstream proteins, which play functional roles in
cell survival, proliferation vascular permeability and
stabilization of new blood vessels [4-6]. For example,
VEGF induces endothelial cell proliferation by activating
the protein kinase Ras-MEK-extracellular signal-regulatedl Ltd. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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VEGF/VEGFR-2 are mediated by the PI3K/AKT pathway
[7]. Accordingly, the VEGF signaling pathway has become
an important target for anti-cancer treatment and many
approaches have been developed to inhibit this pathway
[8,9].
Indirubin has been shown to be the active component
of the traditional Chinese herbal medicine, Danggui
Longhui Wan, which is used to treat chronic myelogen-
ous leukemia [10]. Various indirubin derivatives (IDRs)
have been found to act as potent inhibitors of cyclin-
dependent kinase (CDK)1/cyclin B, CDK2/cyclin A,
CDK2/cyclin E, glycogen synthase kinase-3β and CDK5/
p25, displaying potent growth inhibitory effects in several
tumor cells [11-14]. Among the indirubin derivatives,
IDR-E804 has been established as a strong inhibitor of
signal transducer and activator of transcription (STAT)-3
signaling in human breast and prostate cancer cells [15].
In addition, IDR-E804 directly inhibits c-Src kinase
activity in vitro and causes reduced phosphotyrosyl c-Src
levels in human cancer cells [15]. Although the anti-
cancer activity of IDR-E804 has been demonstrated in
human breast and prostate cancer cells [15], the effect
on angiogenesis, which is critical in cancer development,
is still unknown.
Here, we report that IDR-E804 inhibited endothelial
cell proliferation, migration and tube formation in vitro
assays using human umbilical vein endothelial cells
(HUVECs). In addition, IDR-E804 inhibited tumor
growth via a reduction in CD31- and Ki-67-positive cells
and increased apoptosis in the allograft colon tumor
model. Furthermore, mechanistically, IDR-E804 directly
inhibits VEGFR-2 kinase activity in vitro and causes a re-
duction of phosphorylation of VEGFR-2, AKT and ERK
in VEGF stimulated HUVECs. Our studies suggest that
IDR-E804 is a novel angiogenesis inhibitor and could




IDR-E804 was purchased from Calbiochem (Gibbstown,
NJ). A 40 mM solution of IDR-E804 was prepared in di-
methyl sulfoxide (Sigma-Aldrich, St. Louis, MO), stored
at -20°C, and then diluted as needed with cell culture
medium for in vitro experiments or with PBS for animal
experiments. Recombinant human and mouse VEGF was
obtained from eBioscience (San Diego, CA). Matrigel
was purchased from BD Biosciences (San Jose, CA). The
antibodies used in this study were anti-phospho-VEGFR-2
rabbit polyclonal, anti-VEGFR-2 rabbit polyclonal, anti-
phospho-AKT rabbit polyclonal, anti-AKT rabbit poly-
clonal, anti-phospho-JNK rabbit polyclonal, anti-JNK, anti-
phospho-pERK1/2 rabbit polyclonal, anti-ERK1/2 rabbitpolyclonal (Cell Signaling Technology, Danvers, MA), and
anti-β-actin mAb (Sigma-Aldrich).
Cell line and proliferation assay
HUVECs were obtained from Lonza (Walkersville, MD)
and cultured in EGM (Lonza) at 37°C in an atmosphere
with 5% CO2. The effects of IDR-E804 on cell prolifera-
tion were tested using the CellTiter 96W AQueous One
Solution Cell Proliferation Assay (Promega, Madison,
WI).
Migration assay
HUVECs were allowed to grow to full confluence in 24-
well plates that were precoated with 0.1% gelatin and
then incubated with 10 μg/mL mitomycin C (Sigma-
Aldrich) at 37°C in a 5% CO2 atmosphere for 2 h to in-
activate HUVECs. Monolayer inactivated HUVECs were
scratched by a 0.1 mL pipette tip. Fresh medium con-
taining various concentrations of IDR-E804 was then
added, and images were taken under the AxioImager M1
microscope (Carl Zeiss, Gottingen, Germany) after 8 h of
incubation at 37°C.
Tube formation assay
Matrigel was thawed at 4°C overnight, after which each
well of prechilled 24-well plates was coated with 150 μL
Matrigel and incubated at 37°C for 45 min. HUVECs
(4 × 104 cells) were then added in 1 mL EGM and incu-
bated with the indicated amount of IDR-E804 at 37°C in
a humidified 5% CO2 atmosphere. After 16 h of incuba-
tion, the medium was removed and rhodamine-labeled
phalloidin (Thermo SCIENTIFIC, Rockford, IL) was
added to stain the F-actin. Next, images of fluorescently
labeled cells were collected using a ThermoScientific
Cellomics ArrayScan High Content Screening Reader
(Cellomics, Pittsburgh, PA) and analyzed by an auto-
mated algorithm that identified the tubes formed by the
association and clustering of the endothelial cells [16].
Aortic ring assay
Forty-eight-well plates were covered with 0.1 mL of
Matrigel at 4°C and then incubated at 37°C under 5%
CO2 for 30 min. Aortas isolated from SD rats (KOA-
TECH, Pyeongtek, Korea) were cleaned of periadventitial
fat and connective tissues, after which they were cut into
1-mm- to 1.5-mm-long rings. After being rinsed with
PBS, the aortas were placed on the Matrigel-covered
wells and covered with another 0.1 mL of Matrigel. Ar-
tery rings were cultured in 0.5 mL of EGM without
serum for 24 h, after which the medium was replaced
with 1.5 mL of EGM with vehicle or IDR-E804 (0.5, 1, 5
and 10 μM). The medium was changed every two days
with fresh medium of the exact composition as described
above. After seven days, the microvessel growth was
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inverted microscope (Carl Zeiss) using a 4x objective
lens.
VEGFR-2 inhibition assay
A 12.5 μL aliquot of the 4x reaction cocktail containing
100 ng VEGFR-2 [supplied from the HTScan VEGFR-2
kinase assay kit (Cell Signaling Technology)] was incu-
bated with 12.5 μL of IDR-E804 for 5 min at room
temperature. A 25 μL aliquot of 2x ATP/substrate pep-
tide cocktail was then added to the preincubated reaction
cocktail/IDR-E804 compound. After incubation at room
temperature for 30 min, 50 μL of stop buffer (50 mM
EDTA, pH 8) were added to each tube to stop the reac-
tion. Next, 25 μL of each reaction were transferred into a
96-well streptavidin-coated plate containing 75 μL H2O/
well and the samples were then incubated at room
temperature for 60 min. After washing the wells three
times with 200 μL/well PBS/T (0.05% Tween 20 in
1×PBS), 100 μL of primary antibody [phosphorylated tyro-
sine monoclonal antibody (pTyr-100), 1:1000 in PBS/T
with 1% bovine serum albumin (BSA)] were added per well.
After being incubated at room temperature for 60 min, the
wells were washed three times with 200 μL PBS/T, after
which 100 μL of diluted HRP-labeled anti-mouse IgG
(1:500 in PBS/T with 1% BSA) were added per well. Fol-
lowing incubation at room temperature for 30 min, the
wells were washed five times with 200 μL of PBS/T per
well. Subsequently, 100 μL of TMB substrate were added
per well, and the plate was incubated at room
temperature for 15 min. Stop solution (100 μL/well) was
then added, and the samples were mixed and incubated
at room temperature for 15 min. The plate was then
read at 405 nm using a SpectraMax M2 microplate
reader (Molecular Devices, Sunnyvale, CA).
Western blot
HUVECs were treated with 0-10 μM IDR-E804 with or
without human recombinant VEGF (10 ng/mL) for 30
min. Next, 10 μg of total cellular protein from each sam-
ple were subjected to western blotting with the indicated
antibodies and immunoreactive proteins were detected
using a chemiluminescence Western blotting detection
system (ECL PlusTM Western Blotting Reagents, Amer-
sham Biosciences, Boston, MA).
In vivo murine tumorigenesis assay
Five-week-old BALB/c male mice (KOATECH, Korea)
weighing 20 g were divided into groups (5 mice/group).
5 × 105 cells in 50 μl of PBS were mixed with 50 μl of
matrigel and injected subcutaneously in the right hind
flank of animals. Approximately five days after implant-
ation when the tumors reached a volume of approxi-
mately 150 to 200 mm3, intratumor injections weregiven with 100 μL of vehicle (0.1% of DMSO in DW)
or 200 μM (7.31 μg/animal) of IDR-E804 daily using a
26-gauge needle. Body weight and tumor volume were
subsequently determined every two days by direct mea-
surement with calipers (Mitutoyo Corporation, Japan).
Tumor sizes were measured (tumor volume = ab2/2 in
mm3, where a and b are the longest and the shortest
perpendicular diameters of the tumor, respectively), and
tumor weights were taken at termination on day 20. All
animal studies were conducted under a protocol
reviewed and approved by the Hallym University Institu-
tional Animal Care and Use Committee.
Immunohistochemistry
Tumors were removed 20 days after CT-26 cell injection
and fixed with 4% paraformaldehyde for at least 24 h.
The fixed tumors were embedded in paraffin, sectioned
into 6-μm-thick sections, deparaffinized, and stained
with hematoxylin and eosin. Apoptotic cells in the
tumors were labeled by the terminal deoxyribonucleoti-
dyl transferase-mediated dUTP-digoxigenin nick end-
labeling (TUNEL) method using an In Situ Apoptosis
Detection Kit (R&D Systems, Minneapolis, MN) accord-
ing to the manufacturer’s instructions. Proliferating cells
and platelet endothelial cell adhesion molecule-positive
cells were assessed by the immunoperoxidase technique
using an anti-Ki-67 antibody (Lab Vision, Fremont, CA)
or anti-CD31 antibody (Santa Cruz Biotechnology, Santa
Cruz, CA). Images were taken with an AxioImager M1
microscope (Carl Zeiss) and quantified by counting
the number of positively stained cells in 15 randomly
selected fields at x200 or x400 magnifications.
Statistical analyses
The data are depicted as the means± S.E. The values were
evaluated by one-way analysis of variance (ANOVA) with
Bonferroni multiple comparison post tests using the
GraphPad Prism 4.0 software (GraphPad Software Inc.,
San Diego, CA). A p-value of less than 0.05 was considered
to be statistically significant.
Results
IDR-E804 blocks angiogenesis in vitro
Endothelial cell proliferation, migration and capillary
tube formation are important events during angiogenesis.
We first tested whether IDR-E804 inhibits proliferation
in VEGF-treated HUVECs. Using an MTS assay, we
measured HUVECs proliferation after treatment with
various concentrations of IDR-E804 (0-10 μM). As
shown in Figure 1A, IDR-E804 reduced cell prolifera-
tion in a concentration-dependent manner in VEGF-
stimulated HUVECs.
We next measured the effect of IDR-E804 treatment
on the migration of HUVEC cells using a scratch assays.
Figure 1 Inhibition of endothelial cell proliferation, migration, and capillary-like tubule formation by IDR-E804. (A) HUVECs were plated
in 96-well plates, allowed to attach overnight, and then cultured for 24 h with vehicle or the indicated concentration of IDR-E804. The
proliferation was measured as described in the Materials and Methods section. (B) For cell migration, a monolayer of inactivated HUVECs was
scratched by a 0.1-mL pipette tip, and fresh medium containing vehicle or IDR-E804 was then added. After 24 h, migration of HUVECs was
quantified. Original magnification, ×40. (C) For capillary-like tubule formation, HUVECs (4 × 104/well) were seeded onto Matrigel-coated 24-well
plates and incubated with vehicle or IDR-E804 at 37°C for 16 h. Endothelial tubules were then photographed and quantitated. Original
magnification, ×40. The results shown are the means ± S.E. of four independent experiments conducted in triplicate. *P< 0.05, **P< 0.01,
***P< 0.001 versus VEGF-treated HUVECs.
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of HUVECs were scratched with 0.1 mL tip and the ini-
tial distance was 450 ± 12 μm. In vehicle-treated controls,
a large fraction of HUVECs migrated as shown in Figure
1B. IDR-E804 strongly inhibited the migration of HUVECs
in a dose-dependent manner (Figure 1B).
When HUVECs are plated on a basement membrane
matrix (Matrigel) in short-term culture, they align into
networks of tubules (Figure 1C). This process is dependent
on the proteolytic degradation of the matrix, cell realign-
ment, and apoptosis; however, directed cell migration and
proliferation are not involved in this process [17]. To
evaluate tube formation by endothelial cells in a quantita-
tive manner, tube length was measured using an imaging
analyzer as previously described [16]. IDR-E804 reduced
HUVEC tubule formation in a concentration-dependent
manner (Figure 1C), with a significant reduction being
observed at 0.5-10 μM. These data indicate that IDR-E804
has an anti-angiogenic effect in VEGF treated HUVECs.IDR-E804 inhibits microvessel outgrowth from the rat
aortic ring
We next evaluated the anti-angiogenic effects of IDR-E804
in an ex vivo aorta sprout outgrowth assay. The 1-mm- to
1.5-mm-long aortic rings were placed on Matrigel and
covered by another Matrigel layer and EGM with or
without IDR-E804. After seven days of incubation, the
numbers of microvessel outgrowths from the aortic
rings in the presence or absence of IDR-E804 were com-
pared. As shown in Figure 2, the presence of 0.5-10 μM
IDR-E804 inhibited microvessel sprouting from the ratFigure 2 Effect of IDR-E804 on microvessel outgrowth arising from ra
Matrigel in 48-well plates and then fed with medium containing IDR-E804 f
experiments. Original magnification, ×40.thoracic aorta, suggesting that IDR-E804 inhibited
angiogenesis.
IDR-E804 inhibits the VEGFR-2 signaling pathway and activity
To determine if treatment with IDR-E804 inhibits the ac-
tivation of VEGFR-2 and its multiple downstream signal-
ing pathways, we next examined the levels of the
phosphorylated-VEGFR-2, -ERK, -JNK and AKT proteins
in IDR-E804 treated HUVECs. VEGFR-2 was phosphory-
lated by exogenous VEGF treatment in HUVECs as
shown in Figure 3A, and IDR-E804 treatment reduced
this phosphorylation. IDR-E804 also dose-dependently
inhibited the phosphorylation of ERK and AKT proteins,
a downstream signaling molecule, but not c-Jun N-
terminal protein kinases, reaching almost basal levels at
1-10 μM (Figure 3A). The total steady state levels of
VEGFR-2, AKT and ERK proteins remained unchanged,
indicating that IDR-E804 specifically interferes with the
phosphorylation of these proteins.
To verify the inhibitory effect of IDR-E804 on VEGFR-
2, we examined the effects of various concentrations of
IDR-E804 on the specific activation of VEGFR-2 using
the HTScanW VEGFR-2 kinase assay kit according to the
suggested protocol (Cell Signaling Technology). IDR-
E804 inhibited VEGFR-2 kinase activity with an IC50
of 0.95 μM (Figure 3B), suggesting that E804 inhibits
VEGFR-2 kinase activity.
IDR-E804 inhibits tumor-angiogenesis and tumor growth
in vivo
Tumor angiogenesis presents nutrients, oxygen, and crit-
ical routes for tumor growth as well as metastasis [18].t aortic rings. Aortic rings isolated from SD rats were embedded in
or seven days. Photographs are representative of three independent
Figure 3 Inhibition of VEGFR-2 signaling by IDR-E804. (A) HUVECs were incubated with VEGF (10 ng/mL) and the indicated concentration of
IDR-E804 for 30 min. Total cell lysates were prepared, proteins were separated by SDS–PAGE, and Western blot analysis was conducted.
Photographs of chemiluminescent detection of the blots representative of four independent experiments are shown. Band intensity was
quantified by densitometry and each bar represents the mean± S.E. *P< 0.05, **P< 0.01, ***P< 0.001 versus VEGF-treated HUVECs. (B) Inhibition of
VEGFR-2 activation by IDR-E804 in a specific VEGFR-2 inhibition assay. The results are reported as the mean± S.E. of triplicate assays.
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IDR-E804 was assessed using murine colon carcinoma
CT-26 cells inoculated subcutaneously into syngeneic
BALB/c mice. As shown in Figure 4B, IDR-E804 daily
treatment (total 15 times) did not alter the body weight,
but the average tumor size of the control group was
1576 ± 260 mm3 while that of the IDR-E804 treated
group was 798 ± 212 mm3 at day 20 after injection of
tumor cells (Figure 4A). The average tumor weight of
the control group was 0.79 ± 0.03 g, while that of the
IDR-E804 treated group was 0.42 ± 0.09 g (Figure 4D) at
day 20 after injection of tumor cells, indicating that IDR-
E804 significantly inhibited tumor growth.To examine the effect of IDR-E804 on tumor angio-
genesis, we stained the tumor sections with the specific
endothelial cell marker, CD31 protein. Vehicle-treated
mice showed 1863 ± 379 μm2 CD31-immunoreactive
areas per field, whereas IDR-E804-treated mice showed
703 ± 102 μm2 per field (Figure 5), indicating that IDR-
E804 significantly inhibited tumor angiogenesis and
thereby prevented tumor growth.
We next tested whether IDR-E804 causes histological
changes in tumor tissue by measuring proliferation and
apoptosis using Ki-67 and TUNEL staining, respectively.
In similar fields of view, IDR-E804 mice showed fewer pro-
liferative cells and more apoptotic cells than control mice
Figure 4 IDR-E804 inhibits the growth of mouse tumors. CT-26 cells were injected subcutaneously into the right flank. After tumor formation,
mice were treated with vehicle or IDR-E804 and scarified at day 20 after injection of tumor cells for the analysis. (A) Tumor growth after IDR-E804
treatment. Tumor sizes were measured daily with a caliper. (B) Changes in the body weight of mice treated with vehicle or IDR-E804. (C)
Macroscopic features of tumors isolated from vehicle or IDR-E804 treated mice. (D) Tumor weight of vehicle or IDR-E804 treated mice. The results
shown are the means ± S.E. of two independent experiments conducted. *P< 0.05, **P< 0.01, ***P< 0.001 versus vehicle treated animals.
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inhibits tumor angiogenesis, and subsequently promotes
apoptosis and reduces tumor progression.
Discussion
IDR-E804 is a cell-permeable indirubin derivative that
blocks the STAT-3 signaling pathway [15]. Previous stud-
ies have demonstrated that IDR-E804 is a promising
anti-cancer agent because it is able to inhibit the prolif-
eration and induce the apoptosis of various human can-
cer cells [15]. IDR-E804 has also been shown to be a
potent, reversible, and ATP-competitive inhibitor of the
kinase activities of Src, Cdk1/cyclin E, Cdk2/cyclin A,
and Cdk1/cyclin [15]. This compound has also been
shown to reduce the phosphorylation levels of Src, JAK1,
and STAT-3 in MDA-MB-468 human breast cancer cells
[15]. In addition to the inhibitory activities of Src, Cdk1/
cyclin E, Cdk2/cyclin A, and Cdk1/cyclin, the apoptotic
effect of IDR-E804 has been shown to occur in response
to the down-regulation of anti-apoptotic proteins Mcl-1
and survivin. These anti-cancer effects of IDR-E804 in
various human cancer cells led us to investigate the role
of IDR-E804 in angiogenesis, which is essential for can-
cer development [1-3].
The present study provides evidence that IDR-E804
is a VEGFR-2 inhibitor that inhibits angiogenesis andtumor progression. Our work focused on the inhibitory
effects of IDR-E804 on the proliferation, migration and
tube formation in HUVECs, which are critical steps
involved in endothelial angiogenesis. Due to the inhib-
ition of VEGFR-2 phosphorylation and activation, IDR-
E804 reduced the ERK and AKT signaling pathway in
HUVECs (Figure 3). We also found that IDR-E804 dir-
ectly inhibited the kinase activity of purified VEGFR-2, a
novel activity of IDR-E804 that has not yet been charac-
terized. To the best of our knowledge, this is the first
study to demonstrate the inhibitory effect of IDR-E804
on angiogenesis via inhibition of VEGF/VEGFR-2 signal-
ing, at least in part. We also demonstrated that IDR-
E804 effectively suppresses the growth of CT-26 colorec-
tal cancer grafts via inhibition of angiogenesis as well as
acceleration of apoptosis (Figures 4 and 5). Since previ-
ous results indicated that IDR-E804 inhibits Src kinase
activity and STAT-3 phosphorylation in various cancers
which are critical for angiogensis [19,20], it is possible
that IDR-E804 inhibits angiogenic process via Src and/or
STAT-3 signaling pathways, but the detail action of IDR-
E804 on Src and STAT-3 activation in HUVECs requires
further investigation.
Our in vitro studies with HUVECs demonstrated
that IDR-E804 inhibited the proliferation, migration and
capillary-like structure formation in VEGF-stimulated
Figure 5 IDR-E804 inhibits angiogenesis and cell proliferation
and induces apoptosis in mouse tumors. (A)
Immunohistochemistry was performed in tumor tissues derived from
vehicle and IDR-E804 treated mice on day 20 to measure
angiogenesis by CD31 staining, cell proliferation by Ki-67 staining
and apoptosis by TUNEL assay. Original magnification, ×200. (B)
Quantitation of CD31 vessel staining, Ki-67 staining, and TUNEL
staining from immunohistochemical analyses are shown. Results are
the mean± S.E. of 20 sections per group. *P< 0.05, **P< 0.01,
***P< 0.001 versus vehicle-treated animals.
Shin and Kim BMC Cancer 2012, 12:164 Page 8 of 10
http://www.biomedcentral.com/1471-2407/12/164HUVECs (Figure 1). A similar phenomenon was
observed in the rat aortic ring assay (Figure 3), suggest-
ing that IDR-E804 inhibits microvessels formation. Endo-
thelial cell signaling in response to VEGF is well
established [4-7]. VEGF is one of the most potent tumor
angiogenic factors that promotes the proliferation and
migration of endothelial cells and increases vascular per-
meability [5-8]. It is well known that VEGF and its
receptors are important mediators during different steps
of angiogenesis in cancer [21]. For its multifunction,
VEGF activates a diverse and integrated network of sig-
naling pathways. These different signaling cascades play
different roles in the biological functions and also cross-
talk to each other. The survival effect of VEGF activation
is primarily mediated by the AKT pathway. AKT not
only inhibits the pro-apoptotic proteins and apoptotic
caspases, but also up-regulates the anti-apoptotic pro-
teins [22]. ERK signaling has been implicated in the pro-
liferation, survival, and protection against receptor-
mediated apoptosis of endothelial cells [23]. Moreover,
ERK signaling is thought to stimulate angiogenesis by
promoting endothelial cell motility [24]. In the present
study, the phosphorylation of the AKT and ERK of
HUVECs was increased upon VEGF stimulation and
IDR-E804 significantly reduced AKT and ERK phosphor-
ylation. These results indicate that E804 inhibits prolif-
eration and migration of endothelial cells via inhibition
of AKT and ERK.
The present study indicates that IDR-E804 (20 μM) ef-
fectively suppressed tumor volume and tumor weight
(Figure 4A and 4D) without adverse effects on mouse
body weight (Figure 4B) via inhibition of angiogenesis as
well as acceleration of apoptosis in allograft colon tumor
mice (Figure 5). Previous studies demonstrated that IDR-
E804 induced apoptosis in transformed MDA-MB-468
human breast cancer cells, but did not induce apoptosis
in normal MCF-10A cells. In addition, Mcl-1 and survi-
vin expression is dramatically reduced in response to
IDR-E804 and apoptosis is induced in breast cancer cells
[15]. Our immunohistochemistry results revealed that
the generation of new blood vessels and Ki-67 positive
cells in the treated group were reduced when compared
with the control groups (Figure 5). Moreover, the num-
bers of TUNEL positive cell were significantly higher in
IDR-E804 treated tumor sections (Figure 5). These find-
ings indicate that IDR-E804 induced the apoptosis in
cancer cells as well as tumor tissues in mice.
Previous studies demonstrated that indirubin
(C16H10N2O2) and indirubin-3’-monoxime (C16H11N3O2),
an indirubin derivative, are potential drug candidates for
angiogenesis related diseases [25,26]. Indirubin inhibited
prostate tumor growth mainly through antitumor angio-
genesis via blocking VEGFR-2 mediated STAT-3 signaling
pathway in endothelial cell [26]. In addition, indirubin-3’-
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capillary-like structure formation of HUVECs [25]. Com-
paring previous study, IDR-E804 exerted anti-angiogencic
activity in HUVECs at lower concentration than indirubin
and indirubin-3’-monoxime. The inhibited concentration
of indirubin and indirubin-3’-monoxime against the prolif-
eration, migration as well as tube formation of HUVECs
was 25-100 μM and 2.5-20 μM, respectively [25,26]. Al-
though indirubin blocked the phosphorylation of VEGFR-
2, the concentration which blocks the phosphorylation of
VEGFR-2 was 25-100 μM whereas IDR-E804 was 1-10
μM. Although additional work is needed to elucidate the
relationship between the structure and anti-angiogenic ac-
tivity of indirubin or other indirubin derivatives, IDR-E804
might have powerful potential to inhibit angiogenesis than
indirubin and indirubin-3’-monoxime.
It should be noted that this in vivo study has a few lim-
itations. Since we tested only a single dose of IDR-E804
for the in vivo mouse experiments, detailed dose-
response effect of IDR-E804 on angiogenesis and tumor
growth in vivo needs to be investigated. In addition, pre-
clinical studies to test the safety of IDR-E804 in vivo
should be conducted to determine if it is suitable for fur-
ther use as an anti-cancer and anti-angiogenic agent.
Conclusion
In summary, our studies show that IDR-E804 functions
as an inhibitor of the VEGFR-2 signaling pathway, lead-
ing to inhibition of angiogenesis. Our data suggest a new
mechanism of action for IDR-E804 and its potential use
as an anti-angiogenic and anti-cancer agent.
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